-
Bayer Inks Licensing Deal for Suzhou Puhe’s PRMT5 Inhibitor, BAY 3713372
•
German pharmaceutical giant Bayer (ETR: BAYN) has entered into a licensing agreement with Suzhou Puhe Biopharma Co., Ltd, acquiring global exclusive development, manufacturing, and commercialization rights to the Chinese firm’s MTA-cooperative PRMT5 inhibitor, designated as BAY 3713372. Financial details of the deal were not disclosed. Bayer has enrolled the first…
-
AstraZeneca’s Calquence Approved by NMPA for CLL/SLL Treatment
•
UK pharmaceutical major AstraZeneca (NASDAQ: AZN) has announced receiving another indication approval from China’s National Medical Products Administration (NMPA) for its Calquence (acalabrutinib). The drug is now approved for use in adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) as a monotherapy. This marks the third…
-
Shanghai ZJ Bio-Tech’s HCV Nucleic Acid Test Kit Receives NMPA Approval
•
China-based molecular diagnostic reagent specialist Shanghai Liferiver Bio-Tech Co., Ltd (SHA: 688317) has announced receiving Category III medical device license from the National Medical Products Administration (NMPA) for its hepatitis C virus (HCV) nucleic acid test kit (fluorescent PCR method). This product is designed for the quantitative detection of HCV…
-
Shanghai RAAS Plans RMB4.2 Billion Acquisition of Nanyue BioPharming to Boost Plasma Resources
•
China’s Shanghai RAAS (SHE: 002252) has announced plans to acquire 100% stakes in compatriot firm Nanyue BioPharming Co., Ltd, one of the first blood products companies in the country, for RMB4.2 billion (USD578 million) in cash. The acquisition aims to ramp up RAAS’ plasma resources and high-quality production base. Acquisition…
-
Sichuan Huiyu Pharmaceutical Wins Marketing Approvals in Italy, Portugal, Saudi Arabia
•
China-based Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553) has announced its its subsidiaries Seacross Pharma (Europe) and Seacross Pharmaceuticals Ltd. receiving a series of marketing approvals for its products in Italy, Portugal, and Saudi Arabia. The approved products include valproate concentrated solution, zoledronic acid, teicoplanin, and plerixafor. Valproate Concentrated SolutionValproate,…
-
Merck KGaA Partners with Roche to Commercialize Tepmetko in China
•
Germany-based pharmaceutical giant Merck KGaA (ETR: MRK) has entered into a partnership with Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) to commercialize its lung cancer targeted drug Tepmetko (tepotinib) in mainland China. This collaboration aims to leverage the strengths of both companies to bring Tepmetko to more patients in need.…
-
China Resources Medical Holdings Reports 2024 Revenue of RMB9.86 Billion Amid Net Profit Surge
•
China Resources Medical Holdings Company Ltd (CR Medical, HKG: 1515) has published its 2024 financial report. The company recorded revenues of RMB 9.86 billion (USD 1.4 billion), marking a 2.5% year-on-year (YOY) decrease. Despite the revenue decline, net profits rose significantly by 104.9% YOY to RMB 672 million (USD 92.5…
-
GSK’s Blujepa Approved by FDA for Uncomplicated Urinary Tract Infections
•
UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its drug Blujepa (gepotidacin). The approval allows the use of Blujepa in female adults (≥40 kg) and pediatric patients (≥12 years, ≥40 kg) with uncomplicated urinary tract…
-
Guangzhou Doublle Bioproduct Receives IND Approval for E101 in Type 2 Diabetes
•
Guangzhou Doublle Bioproduct Co., Ltd. has announced receiving Investigational New Drug (IND) clearance from China’s National Medical Products Administration (NMPA) for its E101, a human umbilical cord mesenchymal stem cells (HUC-MSCs) product. The approval allows the company to initiate clinical trials for the treatment of type 2 diabetes (T2D). Product…
-
WuXi Biologics Reports 9.6% Revenue Growth in 2024, Expanding CRDMO Services
•
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has released its 2024 financial report, recording revenues of RMB 18.68 billion (USD 2.57 billion) after a 9.6% year-on-year (YOY) increase. Non-COVID revenue grew by 13.1% YOY, driven by successful execution of the company’s strategies, expanded service offerings,…
-
Sanofi’s Tolebrutinib Accepted for FDA Review in Non-Relapsing Secondary Progressive Multiple Sclerosis
•
Sanofi (EPA: SAN, NASDAQ: SNY) announced that a market filing for its tolebrutinib as a treatment for non-relapsing secondary progressive multiple sclerosis (nrSPMS) has been accepted for review by the US FDA. The agency is expected to make its decision by September 28, 2025. A regulatory submission is also under…
-
Fosun Pharma’s 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its 2024 financial report, recording revenues of RMB 41.1 billion (USD 5.7 billion), a slight decrease of 0.80% year-on-year (YOY). The net profit attributable to the parent company reached RMB 2.77 billion (USD 381 million), marking a…
-
Burning Rock Reports Q4 Revenue Growth Amid Improved Profitability
•
Guangzhou-based medical device company Burning Rock (NASDAQ: BNR) has released its Q4 2024 financial results. The company reported Q4 revenues of RMB 126 million (USD 17.3 million), representing a 4.1% year-on-year (YOY) increase. For the full year, revenues reached RMB 515.8 million (USD 71 million), a 4.0% YOY decrease. Despite…
-
Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab
•
Alphamab Oncology (HKG: 9966) has announced its 2024 financial results, marking a significant milestone with its first annual profit. The company reported revenues of RMB 640.08 million (USD 88.1 million), representing a 192.58% year-on-year increase. Profits reached RMB 166.34 million (USD 22.9 million), driven primarily by sales of its core…
-
Shanghai Henlius Biotech Receives NMPA Approval for HLX79 in Glomerulonephritis Trial
•
China’s Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study for its HLX79 (E-602) in combination with Hanlikang (rituximab biosimilar) for the treatment of active glomerulonephritis. Innovation and MechanismHLX79 is a first-in-class human sialidase fusion…
-
Chia Tai Tianqing’s TQB2210 Approved for Advanced Malignant Tumor Study
•
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved Chia Tai Tianqing’s Category 1 drug TQB2210 for clinical study in advanced malignant tumors. This marks a significant step forward for the company in the field of oncology. Drug Profile and InnovationTQB2210 is a human…
-
CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access
•
China-based CanSino Biologics Inc. (HKG: 6185) has entered into a collaboration agreement with Saudi pharmaceutical firm SPIMACO, a leader in the Middle East and North Africa (MENA) region. The partnership aims to enhance access to CanSino’s ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia) in Saudi Arabia and other…
-
Everest Medicines Reports Surge in Revenue, Advances Core Products and R&D Pipeline
•
China-based Everest Medicines (HKG: 1952) has announced its 2024 financial results, marking a significant milestone in its growth trajectory. The company reported a remarkable 461% year-on-year increase in revenues, reaching RMB 707 million (USD 97 million). Concurrently, the non-IFRS net loss narrowed by 25% to RMB 537.6 million (USD 74…
-
Jiangsu Hengrui Pharmaceuticals Inks Global License Deal with Merck for HRS-5346
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced a license agreement with US-based giant Merck & Co., Inc. (NYSE: MRK). Under the terms, Merck gains exclusive global development, manufacturing, and commercialization rights to Hengrui’s HRS-5346, excluding the Greater China region. Financial TermsMerck will provide an upfront payment of USD 200…
-
Sichuan Kelun-Biotech Gains NMPA Approval for SKB107 Bone Metastasis Trial
•
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its drug candidate SKB107, formerly known as TBM-001. The study will focus on advanced solid tumor bone metastasis. Drug Development and MechanismSKB107 is a radionuclide…
